| DC10388 |
(R)-BPO-27 |
(R)-BPO-27 is a potent CFTR inhibitor with an IC50 of 4 nM |
-BPO-27.gif)
|
| DC12003 |
Corr4A
Featured
|
A small molecule corrector of ΔF508-CFTR with IC50 of 6.0 uM.. |
|
| DC10387 |
BPO-27 racemat |
BPO-27 racemate is a potent CFTR inhibitor with an IC50 of 8 nM. |
|
| DC7039 |
CFTR Inhibitor II
Featured
|
CFTR Inhibitor II is a cell-permeable glycinyl hydrazone compound that acts as a potent, selective and reversible open-channel blocker of CFTR with intermediate speed (< 1 min; 95% inhibition at 50 µM; Ki = 4.3 µM in CFTR-expressing FRT cells. |
|
| DC10753 |
GLPG-1837(ABBV-974)
Featured
|
GLPG-1837(ABBV-974) is a novel cystic fibrosis transmembrane conductance regulator CFTR potentiator. |
|
| DC11678 |
GLPG-2222 |
GLPG-2222 (ABBV-2222, Galicaftor) is a novel potent and efficacious CFTR corrector with EC50 of 5 nM. |
|
| DC7172 |
IOWH-032 |
iOWH032 is a novel and potent CFTR inhibitor (IC50=1.01 uM) in T84 and CHO-CFTR cell based assays. |
|
| DC4128 |
Ivacaftor (VX-770)
Featured
|
Ivacaftor (VX-770, Kalydeco) is a potentiator of CFTR targeting G551D-CFTR and F508del-CFTR with EC50 of 100 nM and 25 nM, respectively. |
|
| DC9276 |
KM 11060
Featured
|
KM 11060 corrects F508del-CFTR trafficking, increasing the amount of functional CFTR at the plasma membrane (~75%) and Inhibits PDE5 activity. |
|
| DC11096 |
Olacaftor |
Olacaftor (VX-440, VX440) is a next-generation CFTR corrector, showsthe potential to enhance the amount of CFTR protein at the cell’s surface and for treatment of cystic fibrosis.. |
|
| DC7483 |
PPQ-102
Featured
|
PPQ-102 is a potent CFTR inhibitor which can completely inhibited CFTR chloride current with IC 50approximately 90 nM. |
|
| DC7100 |
CFTRinh 172
Featured
|
Voltage-independent, selective CFTR chloride channel blocker (Ki = 300 nM) that alters channel gating. |
|
| DC7531 |
VX661
Featured
|
VX-661 is a second F508del CFTR corrector and is believed to help CFTR protein reach the cell surface. |
|
| DC1059 |
Lumacaftor(vx-809，vx809)
Featured
|
VX-809 is a CFTR modulator with EC50 of 0.1 μM. |
|
| DC28157 |
PG01 |
PG01 is a potent CFTR Cl- channel potentiator. PG01 can correct gating defects of CFTR mutants, is effective on b>E193K, G970R and G551D (CFTR mutants) with Kd values of 0.22 μM, 0.45 μM and 1.94 μM, respectively. PG01 is also effective on ΔF508 (Ka of 0.3 μM). PG01 increases ΔF508-CFTR Cl- current after adding Forskolin. |
|
| DC28703 |
GLPG-3221 |
GLPG-3221 is a potent, orally active corrector of CFTR (cystic fibrosis transmembrane conductance regulator), with an EC50 of 105 nM. GLPG-3221 can be uesd for the treatment of cystic fibrosis. |
|
| DC28791 |
CFTR corrector 4 |
CFTR corrector 4 (Compound 13), an active (R,R)-form enantiomer, is a highly potent and orally active cystic fibrosis transmembrane conductance regulator (CFTR) corrector. CFTR corrector 4 can increase CFTR levels at the cell surface and have the potential for treatment of cystic fibrosis. |
|
| DC41585 |
K41498 TFA |
K41498 TFA is a potent and highly selective CRF2?receptor antagonist with Ki?values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β?and CRF1 receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 TFA can be used for hypotension?study. |
|
| DC42510 |
Ivacaftor-D9 |
Ivacaftor-D9 (CTP-656) is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE Cells. Ivacaftor-D9 acts as an orally active and improved deuterated Ivacaftor analog for cystic fibrosis research. |
|
| DC44162 |
Posenacaftor sodium |
Posenacaftor (PTI-801) sodium is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor sodium is used for the research of cystic fibrosis (CF). |
|
| DC45320 |
Kobusin |
Kobusin is a bisepoxylignan isolated from the Pnonobio biondii Pamp. Kobusin is an activator of CFTR and CaCCgie chloride channels and a inhibitor of ANO1/CaCC (calcium-activated chloride channel) channel. |
|
| DC46166 |
Crinecerfont hydrochloride |
Crinecerfont (SSR-125543) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research. |
|
| DC46859 |
Bamocaftor |
Bamocaftor (VX-659) is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector designed to restore F508del-CFTR protein function. Bamocaftor can be used combine with Tezacaftor and Ivacaftor in cystic fibrosis research. |
|
| DC46860 |
Dirocaftor |
Dirocaftor (PTI-808) is a CFTR potentiator that enhances the function of CFTR protein by opening chloride channels. Dirocaftor can be used for cystic fibrosis (CF) research. |
|
| DC46861 |
Navocaftor |
Navocaftor, as a cystic fibrosis transmembrane regulator (CFTR), is a protein modulator (US 20200377491 Al, example 1). |
|
| DC47702 |
Posenacaftor |
Posenacaftor (PTI-801) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF). |
|
| DC47935 |
NJH-2-057 |
NJH-2-057 is an EN523 OTUB1 recruiter linked to lumacaftor, a drug used to treat cystic fibrosis that binds ΔF508-CFTR. |
|
| DC48019 |
CP-628006 |
CP-628006, a small molecule CFTR potentiator, restores ATP-dependent channel gating to the cystic fibrosis mutant G551D-CFTR. |
|
| DC48190 |
Vanzacaftor |
Vanzacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR) for treating cystic fibrosis. |
|
| DC70204 |
ARN23765 |
ARN23765 (ARN 23765) is a highly potent, pharmacological corrector of the mutant CFTR chloride channel with EC50 of 38 pM in cellular assays;
ARN23765 is more than 5000-fold lower compared to presently available corrector drugs.
ARN23765 also showed high efficacy, synergy with other types of correctors, and compatibility with chronic VX-770 potentiator. |
|
